TABLE 2.

Comparison of SUVmax on 68Ga-FAP-2286 and 18F-FDG PET/CT Images in Primary and Metastatic Tumors

Tumor typen68Ga-FAP-228618F-FDG PET/CTP
Size (cm)Positive tumorsSUVmaxTBRPositive tumorsSUVmaxTBRMedian SUVmax (FAP-2286 vs. 18F-FDG)TBR (FAP-2286 vs. 18F-FDG)
Primary
 Total§463.2 (0.9–11.3)4611.1 (2.5–28.9)9.2 (1.1–31.5)376.9 (1.5–19.1)3.0 (0.9–13.2)<0.001<0.001
 HNC71.7 (1.5–3.4)716.8 (11.0–20.2)13.7 (8.1–15.3)711.0 (4.0–15.6)7.0 (2.9–13.1)0.0430.043
 Breast cancer*61.5 (0.9–7.0)69.9 (6.0–18.3)10.1 (3.9–22.3)46.4 (1.5–17.3)5.0 (1.1–13.2)0.2490.075
 Esophageal cancer44.1 (2.1–9.0)422.9 (10.0–26.4)13.6 (6.3–19.4)411.6 (7.9–18.4)5.8 (4.7–8.6)0.0680.068
 Lung adenocarcinoma22.9 (1.1–4.7)27.5 (5.7–9.3)10.0 (9.2–10.9)26.1 (3.3–8.9)7.1 (4.2–10.0)NANA
 Gastric cancer62.0 (1.2–4.5)69.1 (4.1–13.0)9.2 (4.9–12.7)33.4 (1.7–7.9)2.0 (0.9–4.1)0.0280.028
 Hepatic cancer85.2 (0.9–11.3)811.3 (2.5–28.9)5.2 (1.5–9.4)54.8 (3.1–9.7)1.5 (1.0–3.5)0.9170.028
 Pancreatic cancer73.4 (2.4–5.7)713.0 (10.7–22.7)12.2 (5.7–23.3)66.5 (3.0–8.1)2.9 (1.1–4.4)0.0180.018
 Renal cancer14.5 (NA)16.1 (NA)1.5 (NA)14.1 (NA)2.0 (NA)NANA
 Ovarian cancer54.8 (1.7–6.2)510.8 (6.0–25.6)11.0 (5.0–31.5)59.6 (5.3–12.2)6.9 (2.8–9.3)0.3450.138
Recurrence/mets
 Recurrent tumor (total)92.9 (0.7–5.1)95.8 (2.9–16.5)4.7 (2.2–15.7)33.8 (2.2–7.6)1.1 (0.8–5.4)0.0150.008
 LN mets (total)1071.2 (0.5–6.6)10510.6 (3.0–20.1)9.0 (2.2–30.0)916.2 (1.3–21.2)3.7 (1.0–13.0)<0.001<0.001
 Lung mets210.9 (0.4–1.3)163.4 (0.6–10.2)4.9 (0.9–14.5)193.5 (0.7–7.1)5.0 (1.0–10.2)0.8760.931
 Hepatic mets302.6 (0.9–10.7)276.9 (2.4–12.2)4.1 (0.9–8.4)226.8 (2.1–10.8)2.2 (0.9–3.9)0.484<0.001
 Peritoneal mets70NA698.6 (2.4–15.4)6.7 (1.8–27.0)464.6 (1.5–11.4)2.4 (0.8–8.1)<0.001<0.001
 Subcutaneous mets120.9 (0.6–2.0)128.1 (5.2–12.4)9.3 (6.3–20.4)51.4 (0.7–7.4)1.3 (1.0–11.6)0.0020.002
 Bone mets381.0 (0.4–3.1)386.6 (3.8–13.3)10.1 (2.9–26.7)222.7 (0.9–11.4)2.4 (0.9–19.3)<0.001<0.001
  • * One patient was diagnosed with multifocal breast cancer (4 primary tumors).

  • Local recurrent tumors included glioblastoma (n = 1), HNC (n = 4), hepatic cancer (n = 3), and gastric cancer (n = 1).

  • Lesion size cannot be calculated because of diffuse type of peritoneal metastases (irregular shape).

  • § Primary tumors were not located in 2 patients with head and neck cancer of unknown primary etiology; 2 patients were therefore excluded from analysis. Two patients were diagnosed with synchronous double cancer (one with esophageal and lung adenocarcinoma, the other with HNC and renal cancer).

  • HNC = head and neck cancer; NA = not applicable; mets = metastases; LN = lymph node.

  • Qualitative data are number; continuous data are median and range.